`
`2384
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF DELAWARE
`
`GENENTECH, INC. and CITY OF HOPE,
`
`
`v.
`
`AMGEN, INC.,
`
`Plaintiffs,
`
`Defendant.
`
`
`
`
`
`Case No. 18-924-GMS
`
`
`
`
`
`STIPULATION AND [PROPOSED] ORDER
`TO DISMISS PATENTS AGAINST AMGEN, INC.
`
`IT IS HEREBY STIPULATED AND AGREED by the Parties, subject to the approval of
`
`the Court, that all claims that Amgen, Inc. (“Amgen”) has infringed or will infringe U.S. Patent
`
`Nos. 6,242,177, 6,489,447, 6,586,206, 6,870,034, 7,449,184, 7,501,122, 8,044,017, 8,314,225,
`
`8,357,301, 8,460,895, 8,691,232, 8,710,196, 8,771,988, 9,047,438, 9,080,183, 9,428,766,
`
`9,487,809, 9,493,744, and 9,868,760 (collectively, “the Dismissed Patents” and “Dismissed
`
`Patent” if referring to any of these patents individually) in connection with its drug ABP 980 (the
`
`subject of Amgen’s BLA
`
`) are DISMISSED WITH PREJUDICE. This dismissal pertains
`
`only to Plaintiffs’ claim of infringement with respect to ABP 980 (the subject of Amgen’s BLA
`
`) and does not extend to litigation involving any other product between the Parties.
`
`This dismissal is made without prejudice to Genentech Inc. and City of Hope’s
`
`(collectively, “Plaintiffs”) ability, to be applied on a patent claim-by-patent claim basis, to assert
`
`a Dismissed Patent if (1) Amgen makes a change to its drug product, ABP 980 (the subject of
`
`Amgen’s BLA
`
`), the proposed label for its drug product, or the manufacturing processes
`
`disclosed in Amgen’s BLA
`
`, and that change materially alters the infringement analysis
`
`
`
`ME1 27700554v.1
`
`- 1 -
`
`
`
`PUBLIC VERSION FILED: July 25, 2018
`
`
`
`Case 1:18-cv-00924-CFC-SRF Document 17 Filed 07/25/18 Page 2 of 4 PageID #:
`
`2385
`
`with respect to one or more patent claims of that Dismissed Patent; or (2) Plaintiffs subsequently
`
`discover information not previously provided which establishes that the factual information
`
`provided by Amgen pursuant to 42 U.S.C. §§ 262(l)(2) or factual representation made by Amgen
`
`in the statement provided according to 262(l)(3)(B) was materially inaccurate or incomplete
`
`when provided, and the newly-discovered factual information materially alters the infringement
`
`analysis with respect to one or more patent claims of that Dismissed Patent. In the event that
`
`Plaintiffs reassert a Dismissed Patent under either of those circumstances, the parties reserve
`
`their rights with respect to the application of the limitation on remedies provided in 35 U.S.C. §
`
`271(e)(6)(B) with respect to that Dismissed Patent. Each Party is to bear its own costs, expenses,
`
`and attorneys’ fees associated with this action with respect to the Dismissed Patents.
`
`
`
`
`
`
`
`
`ME1 27700554v.1
`
`- 2 -
`
`
`
`
`
`Case 1:18-cv-00924-CFC-SRF Document 17 Filed 07/25/18 Page 3 of 4 PageID #:
`
`2386
`
`
`
`
`
`
`
`Dated: July 19, 2018
`
`MCCARTER & ENGLISH LLP
`
`
`/s/ Daniel M. Silver
`Michael P. Kelly (#2295)
`Daniel M. Silver (#4758)
`405 North King Street, 8th Floor
`Wilmington, DE 19801
`(302) 984-6300
`mkelly@mccarter.com
`dsilver@mccarter.com
`
`Counsel for Plaintiffs Genentech, Inc. and
`City of Hope
`
`Of Counsel:
`
`William F. Lee
`Lisa J. Pirozzolo
`Emily R. Whelan
`Kevin S. Prussia
`Andrew J. Danford
`WILMER CUTLER PICKERING
`HALE AND DORR LLP
`60 State Street
`Boston, MA 02109
`(627) 526-6000
`william.lee@wilmerhale.com
`lisa.pirozzolo@wilmerhale.com
`emily.whelan@wilmerhale.com
`kevin.prussia@wilmerhale.com
`andrew.danford@wilmerhale.com
`
`Robert J. Gunther Jr.
`WILMER CUTLER PICKERING
`HALE AND DORR LLP
`7 World Trade Center
`250 Greenwich Street
`New York, NY 10007
`robert.gunther@wilmerhale.com
`
`
`
`
`
`
`
`
`
`
`
`
`SMITH, KATZENSTEIN & JENKINS, LLP
`
`
`/s/ Eve H. Ormerod
`Neal C. Belgam (No. 2721)
`Eve H. Ormerod (No. 5369)
`1000 West Street, Suite 1501
`Wilmington, DE 19801
`(302) 652-8400
`nbelgam@skjlaw.com
`eormerod@skjlaw.com
`
`Counsel for Defendant Amgen, Inc.
`
`Of Counsel:
`
`Orion Armon
`Cooley, LLP
`380 Interlocken Crescent, Suite 900
`Broomfield, CO 80021-8023
`(720) 566-4119
`oarmon@cooley.com
`
`Eamonn Gardner
`Cooley, LLP
`4401 Eastgate Mall
`San Diego, CA 92121-1909
`(858) 550-6086
`egardner@cooley.com
`
`Susan Krumplitsch
`Michelle Rhyu
`Daniel Knauss
`Cooley, LLP
`3175 Hanover Street
`Palo Alto, CA 94304-1130
`P 650-843-5287
`skrumplitsch@cooley.com
`mrhyu@cooley.com
`dknauss@cooley.com
`
`
`
`
`
`
`
`
`ME1 27700554v.1
`
`- 3 -
`
`
`
`
`
`Case 1:18-cv-00924-CFC-SRF Document 17 Filed 07/25/18 Page 4 of 4 PageID #:
`
`2387
`
`Daralyn J. Durie
`Adam R. Brausa
`DURIE TANGRI LLP
`217 Leidesdorff St.
`San Francisco, CA 94111
`ddurie@durietangri.com
`abrausa@durietangri.com
`
`
`
`Nancy Gettel
`Thomas Lavery, IV
`Amgen, Inc.
`One Amgen Center Drive
`Thousand Oaks, CA 91320-1799
`P 805-447-1000
`ngettel@amgen.com
`tlavery@amgen.com
`
`
`
`
`
`
`SO ORDERED this ______ day of ____________, 2018.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`____________________________________
`
`United States District Judge
`
`
`
`ME1 27700554v.1
`
`- 4 -
`
`
`
`